Insulins combinations
First Claim
1. A pharmaceutical combination comprising (a) a therapeutic effective amount of an insulin compound selected from the group consisting of insulin, insulin analogues and mixtures thereof, and (b) a therapeutic effective amount of a pharmaceutically acceptable betaine of general formula (CH3)3N+—
- (CH2)n —
COO−
;
with n being an integer from 1 to 5, in which the insulin and the betaine form at least partly a structure selected from the group consisting of chemical entity, chemical complex, physico complex, insulin/betaine micelles, insulin/betaine microstructures, insulin/betaine nanostructures, and combinations thereof, and in which the weight ratio of therapeutic effective amount of the insulin compound/therapeutic effective amount of betaine is between 1;
400 and 1;
5.
0 Assignments
0 Petitions
Accused Products
Abstract
A pharmaceutical association or combination comprising a therapeutic effective amount of insulin or insulin analogue, and a therapeutic effective amount of a pharmaceutically acceptable betaine, in which the insulin and the betaine possibly form a chemical entity or complex, and in which the amount of betaine is adapted for controlling the degradation and/or for increasing the duration of action and/or for enhancing the therapeutically effect of the insulin or insulin analogue.
-
Citations
20 Claims
-
1. A pharmaceutical combination comprising (a) a therapeutic effective amount of an insulin compound selected from the group consisting of insulin, insulin analogues and mixtures thereof, and (b) a therapeutic effective amount of a pharmaceutically acceptable betaine of general formula (CH3)3N+—
- (CH2)n —
COO−
;
with n being an integer from 1 to 5, in which the insulin and the betaine form at least partly a structure selected from the group consisting of chemical entity, chemical complex, physico complex, insulin/betaine micelles, insulin/betaine microstructures, insulin/betaine nanostructures, and combinations thereof, and in which the weight ratio of therapeutic effective amount of the insulin compound/therapeutic effective amount of betaine is between 1;
400 and 1;
5. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12)
- (CH2)n —
-
13. A pharmaceutical composition combining:
-
a form A comprising a pharmaceutically acceptable short-acting insulin compound selected from the group consisting of short-acting insulins and their analogues, said form being free of betaine of general formula (CH3)3N+—
(CH2)n —
COO−
, anda form B comprising a mixture of; a. a pharmaceutically acceptable insulin compound selected from the group consisting of short acting insulins, intermediate-acting insulins, long-acting insulins, analogues thereof and their mixtures, and b. a pharmaceutically acceptable betaine of general formula (CH3)3N+—
(CH2)n —
COO−
;
with n being an integer from 1 to 5. - View Dependent Claims (14, 15, 16, 17, 18)
-
-
19. An isotonic aqueous composition comprising (a) a therapeutic effective amount of an insulin compound selected from the group consisting of insulin, insulin analogues and mixtures thereof, and (b) a therapeutic effective amount of a pharmaceutically acceptable betaine of general formula (CH3)3N+—
- (CH2)n —
COO−
;
with n being an integer from 1 to 5, in which the insulin and the betaine form at least partly a structure selected from the group consisting of chemical entity, chemical complex, physic complex, insulin/betaine micelles, insulin/betaine microstructures, insulin/betaine nanostrucures, and combinations thereof, and in which the weight ratio of therapeutic effective amount of the insulin compound/therapeutic effective amount of betaine is between 1;
100 and 1;
5.
- (CH2)n —
-
20. The pharmaceutical combination of claim l, wherein said combination is in a dosage form suitable for an administration route selected from the group consisting of oral, dermal, transdermal, subcutaneous, parenteral, intraperitoneal, sublingual, nasal, pulmonary, rectal, and combinations thereof.
Specification